Early Recurrence After Liver Resection for Colorectal Metastases: Risk Factors, Prognosis, and Treatment. A LiverMetSurvey-Based Study of 6,025 Patients

2013 ◽  
Vol 21 (4) ◽  
pp. 1276-1286 ◽  
Author(s):  
Luca Viganò ◽  
Lorenzo Capussotti ◽  
Réal Lapointe ◽  
Eduardo Barroso ◽  
Catherine Hubert ◽  
...  
2019 ◽  
Vol 34 (3) ◽  
pp. 269-275
Author(s):  
Felice Giuliante ◽  
Elena Panettieri ◽  
Francesco Ardito ◽  
Agostino De Rose ◽  
Krizia Pocino ◽  
...  

Background: Several prognostic factors were proposed to improve early detection of recurrence after liver resection of metastases of colorectal cancer. Circulating tumor cell-related transcripts were evaluated in colorectal cancer patients with conflicting results. The aim of this study was to investigate usefulness of carcinoembryonic antigen CAM5, epidermal growth factor receptor, and ERCC1 transcripts in the bloodstream as predictive factors of recurrence in patients who underwent liver resection for metastases of colorectal cancer. Methods: Peripheral blood was collected from 29 patients at the time of the colorectal cancer liver metastasis resection, and from 25 normal controls. Follow-up draws (FUDs) were also performed at 30 days, and 3 and 12 months since surgery. On each sample, carcinoembryonic antigen CAM5, ERCC1, and GAPDH mRNAs were examined by quantitative reverse transcription (qRT). Results: Carcinoembryonic antigen transcript levels were linearly correlated to the number of spiked cells (qRT analytical limit = five cells). Among 29 patients (20 M/9 F; mean age 63 years (range 32–79), highly significant levels of carcinoembryonic antigen, if compared to the baseline, were detected in those relapsing after surgery ( P <0.05). The main differences were between the 1st- and 12th-month FUDs. Significantly higher levels of carcinoembryonic antigen were also detected in patients who died from disease progression during the follow-up (as evaluated at 30 days and 90 days FUDs). Conclusions: Blood carcinoembryonic antigen-mRNA absolute copy number overtime variation can represent a valid early predictor of relapse after liver resection in colorectal liver metastases patients. Prospective studies, in the context of large clinical trials, will provide further data to also qualify ERCC1 as a predictive biomarker for decisions on therapeutic strategies.


2021 ◽  
Author(s):  
Hao-Chien Hung ◽  
Jin-Chiao Lee ◽  
Yu-Chao Wang ◽  
Chih-Hsien Cheng ◽  
Tsung-Han Wu ◽  
...  

Abstract Background. Liver resection is a primary curative treatment for early stage hepatocellular carcinoma (HCC), but the outcomes are impeded by early tumor recurrence. This study aimed to establish a prediction model which could predict tumor recurrence outside the Milan criteria prior to liver resection.Methods. A cohort of 891 HCC patients who had curative liver resections were reviewed. HCC recurrence was divided into 4 groups: early recurrence inside the Milan criteria (ER-MI), early recurrence outside the Milan criteria (ER-MO), late recurrence inside the Milan criteria (LR-MI), and late recurrence outside the Milan criteria (LR-MO). The risk factors of ER-MO were analyzed to establish a prediction model.Results: During a median follow-up of 83.4 months, 589 (66.1%) patients developed recurrent HCC. Among 589 patients, 276 (31.0%), 86 (9.6%), 46 (5.2%) and 181(23.3%) patients were in ER-MO, ER-MI, LR-MO and LR-MI groups, respectively. In multivariate analysis of pre-operative factors, large tumors, non-single tumors, high α-fetoprotein level, high neutrophil-to-lymphocyte ratio and high indocyanine green retention were the independent predictors of ER-MO. By adjusting the weight of independent risk factors into scores and stratifying patients into class I, II, III and IV according to score 0, 2-6, 7-10 and ≥11, ER-MO events at 24 months were 12.5%, 22.5%, 45.4% and 66.3% for class I, II, III and IV, respectively (P< 0.05).Conclusions. A risk scoring model was built and could predict ER-MO based on pre-operative factors. This scoring model would be helpful for sharing the decision marking of treatments with patients.


Sign in / Sign up

Export Citation Format

Share Document